Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: The present disclosure relates to methods and apparatus for graphics processing. The apparatus can determine a combined depth map based on at least one of a 3DRU mesh, a DFS map, and a display pose. The apparatus can also determine one or more re-projected eye and depth buffers based on at least one of one or more eye buffers, one or more depth buffers, one or more bounding box and warp parameters, and the display pose. Further, the apparatus can communicate at least one composited frame based on the combined depth map and the one or more re-projected eye and depth buffers. The apparatus can also determine the at least one composited frame based on the combined depth map and the one or more re-projected eye and depth buffers. The apparatus can also combine the 3DRU mesh, the DFS map, and the display pose.

Abstract: Aspects presented herein relate to methods and apparatus for graphics processing. Aspects presented herein can determine at least one split API for a user device and a server. Further, aspects presented herein can establish a communication interface between the user device and the server based on the split API. Additionally, aspects presented herein can communicate between the user device and the server based on the communication interface and the split API. Some aspects presented herein can implement the at least one split API on at least one of the user device or the server. Aspects presented herein can also divide at least one application workload between the user device and the server based on the at least one split API. Moreover, aspects presented herein can encode or decode application information at the user device or the server.

Abstract: The present disclosure relates to methods and apparatus for computer processing. Aspects of the present disclosure can determine at least one of a quality, latency, or capacity of a communication link for communication between a client device and a server. Aspects of the present disclosure can also determine a computational load for an application computation between the client device and the server. Moreover, aspects of the present disclosure can adjust a computational distribution for the application computation between the client device and the server based on at least one of the computational load for the application computation or the at least one of the quality, latency, or capacity of the communication link. Aspects of the present disclosure can also determine a computational capacity of at least one of the client device or the server.

Abstract: A method, a system, and a non-transitory computer readable medium are disclosed for a voice based application blocker. The method includes receiving, on a gateway, a text message from a mobile device; tokenizing, on a processor of the gateway, the text message into at least a user and a purpose, the purpose being denying or granting access of the user to one or more applications from the gateway; and creating, on a firewall of the gateway, blocking rules for the user to the one or more applications from the gateway.

Abstract: This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl-mediated disorders.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A method implementing dynamic camera presets. An image is received. A list of bounding boxes and a list of classification values are generated from the image. A set of tags, for the image, are generated from the list of bounding boxes and the list of classification values. A tagged image incorporating the set of tags into the image is presented. In response to a user input, a tag selection identifying a tag of the set of tags is received. View settings are adjusted to focus on a bounding box, from the list of bounding boxes, corresponding to the tag selection. An adjusted image is presented using the view settings.

Abstract: According to one or more embodiments of the disclosure, a particular networking device joins a ring network of networking devices that has a ring topology. The particular networking device monitors the ring network for a multicast frame used within the ring network to detect link failures. The particular networking device determines that a link in the ring network has failed, based on the particular networking device not receiving the multicast frame within a threshold amount of time. The particular networking device initiates repair of the ring network, when the particular networking device determines that the link in the ring network has failed.

Abstract: This disclosure provides systems, devices, apparatus and methods, including computer programs encoded on storage media, for multi-layer reprojection techniques for augmented reality. A display processor may obtain a layer of graphics data including a plurality of virtual objects. Each the plurality of virtual objects may be associated with at least one bounding box of a plurality of bounding boxes. The display processor may further obtain metadata indicative of at least one edge of the at least one bounding box of the plurality of bounding boxes, and metadata corresponding to reprojection instructions associated with each of the plurality of bounding boxes. The display processor may reproject the plurality of virtual objects based on the metadata indicative of the at least one edge of the at least one bounding box and the metadata corresponding to the reprojection instructions.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

Abstract: An embodiment involves persistent storage and one or more processors. The persistent storage may contain a plurality of hardware models specifying types of computing devices, wherein the hardware models include attributes representing manufacturer names, product names, and model numbers of the computing devices. The processors may be configured to: obtain, from the persistent storage, a hardware model; calculate a hash value over attributes of the hardware model; compare the hash value to hash values in a curated list, the curated list including normalized hardware models that map the hash values to normalized manufacturer names, normalized product names, or normalized model numbers; determine that the hash value matches a particular hash value for a normalized hardware model; and update, in the persistent storage, the hardware model to include at least one of a normalized manufacturer name, a normalized product name, or a normalized model number associated with the normalized hardware model.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.

Abstract: An embodiment involves persistent storage and one or more processors. The persistent storage may contain a plurality of hardware models specifying types of computing devices, wherein the hardware models include attributes representing manufacturer names, product names, and model numbers of the computing devices. The processors may be configured to: obtain, from the persistent storage, a hardware model; calculate a hash value over attributes of the hardware model; compare the hash value to hash values in a curated list, the curated list including normalized hardware models that map the hash values to normalized manufacturer names, normalized product names, or normalized model numbers; determine that the hash value matches a particular hash value for a normalized hardware model; and update, in the persistent storage, the hardware model to include at least one of a normalized manufacturer name, a normalized product name, or a normalized model number associated with the normalized hardware model.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: The present disclosure relates to methods and apparatus for graphics processing. In some aspects, the apparatus may receive, by a first device from a second device, first position information corresponding to a first orientation of the second device. The apparatus can also generate, by the first device, first graphical content based on the first position information. Further, the apparatus can also generate, by the first device, motion information for warping the first graphical content. The apparatus can also encode, by the first device, the first graphical content. Additionally, the apparatus can provide, by the first device to the second device, the motion information and the encoded first graphical content.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: According to one or more embodiments of the disclosure, a particular networking device joins a ring network of networking devices that has a ring topology. The particular networking device monitors the ring network for a multicast frame used within the ring network to detect link failures. The particular networking device determines that a link in the ring network has failed, based on the particular networking device not receiving the multicast frame within a threshold amount of time. The particular networking device initiates repair of the ring network, when the particular networking device determines that the link in the ring network has failed.